A. muciniphila administration might persistently alleviate the microenvironmental inflammation that induce HCC in NASH, for A. muciniphila-treated STAM showed lower IL-6 levels than those in control STAM (Figure 4F). This evidence concerns the gene IL6 and hepatocellular carcinoma.